Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Approval received to expand RAD204 Phase 1 trial

Tuesday, November 19, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has received approval to expand its Phase 1 trial for RAD204. This development marks a significant step in the company's clinical research efforts. The trial expansion is expected to enhance the understanding of RAD204's therapeutic potential. Additionally, the company has reported positive updates across several of its programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval received to expand the RAD204 Phase 1 trial.
  • Positive clinical updates across multiple programs.
  • Engagement of Dr. Oliver Sartor to the scientific advisory board.

Full Press Release Details

• Announcements
• Price Sensitive
• November 19, 2024
Loading Viewer…

More Announcements & Updates

• Updates
• March 18, 2024
• Announcements
• October 19, 2022
• Announcements
• July 2, 2024
• Announcements
• January 21, 2025

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the recent approval regarding RAD204?

Radiopharm Theranostics has received approval to expand its Phase 1 trial for RAD204.

Who has joined the Radiopharm advisory board?

Dr. Oliver Sartor has been appointed to the Radiopharm Scientific Advisory Board.

What does the expansion of the RAD204 trial signify?

The expansion is expected to enhance understanding of RAD204's therapeutic potential.

What other updates has Radiopharm provided?

The company has shared positive clinical updates across several of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics RAD204 Phase 1 trial clinical updates FDA approval
Last updated: Nov 19, 2024